But so far, the company is striking out in its attempts to broaden its label. On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely ...
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...